Dhaka, Nov. 26 -- Bangladesh's private healthcare industry is grappling with a series of structural obstacles, including complex licensing procedures, high reliance on imported medical devices, and slow progress in domestic active pharmaceutical ingredient (API) production. Stakeholders say that addressing these weaknesses is essential as the country prepares for LDC graduation. Business leaders came up with these remarks on Tuesday at an FBCCI discussion titled "Private Sector Participation in Bangladesh's Health Sector: Opportunities and Challenges" called for stronger public-private partnerships, rationalising drug prices, boosting API production, and streamlining the licensing regime.
JMI Group Chairman Abdur Razzaq noted that while Ba...